Table 2.

Incidence of treatment-emergent adverse events by system organ class and preferred term

	GX-19 1·5 mg group (n=20)	GX-19 3·0 mg group (n=20)	GX-19N 3·0 mg group (n=21)
Participants with treatment-emergent adverse events	12 (60%)	8 (40%)	12 (57%)
General disorders and administration site conditions	11 (55%)	4 (20%)	6 (29%)
Chills	0	0	1 (5%)
Fatigue	3 (15%)	0	0
Injection site erythema	2 (10%)	0	1 (5%)
Injection site oedema	1 (5%)	0	0
Injection site pain	6 (30%)	3 (15%)	6 (29%)
Injection site pruritus	5 (25%)	2 (10%)	0
Nervous system disorders	4 (20%)	0	2 (10%)
Cubital tunnel syndrome	0	0	1 (5%)
Headache	3 (15%)	0	1 (5%)
Paresthesia	1 (5%)	0	0
Musculoskeletal and connective tissue disorders	1 (5%)	1 (5%)	2 (10%)
Back pain	0	0	1 (5%)
Myalgia	1 (5%)	0	1 (5%)
Rotator cuff syndrome	0	1 (5%)	0
Somatic dysfunction	0	1 (5%)	0
Gastrointestinal disorders	2 (10%)	1 (5%)	0
Dyspepsia	1 (5%)	0	0
Haematochezia	1 (5%)	0	0
Stomatitis	0	1 (5%)	0
Skin and subcutaneous tissue disorders	0	1 (5%)	3 (14%)
Dermatitis	0	1 (5%)	0
Pruritus	0	0	1 (5%)
Rash	0	0	2 (10%)
Urticaria	0	0	1 (5%)
Infections and infestations	0	2 (10%)	1 (5%)
Appendicitis	0	1 (5%)	0
Folliculitis	0	0	1 (5%)
Vaginal infection	0	1 (5%)	0
Investigations	0	0	1 (5%)
Alanine aminotransferase increased	0	0	1 (5%)
Aspartate aminotransferase increased	0	0	1 (5%)
Reproductive system and breast disorders	0	2 (10%)	1 (5%)
Dysmenorrhoea	0	1 (5%)	1 (5%)
Premenstrual syndrome	0	1 (5%)	0
Hepatobiliary disorders	0	0	1 (5%)
Cholecystitis acute	0	0	1 (5%)
Psychiatric disorders	1 (5%)	0	0
Depression	1 (5%)	0	0
Eye disorders	1 (5%)	1 (5%)	0
Blepharospasm	0	1 (5%)	0
Visual impairment	1 (5%)	0	0

Adverse events defined according to Medical Dictionary for Regulatory Activities (version 24.0).